The solute carrier transporter SLCO5A1 as a novel therapeutic target for the treatment of myocardial infarction-induced heart failure

ACTA PHARMACOLOGICA SINICA · Published 2026-05-27 · DOI 10.1038/s41401-026-01827-4

Free full text

Authors (7)

Ke-yu Liu, Ke Gong, Fang Fang, Qing-hua Chen, Jin-rong Xu, Liang-qing Zhang, Wen-liang Chen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Liu, K., Gong, K., Fang, F., et al. (2026). The solute carrier transporter SLCO5A1 as a novel therapeutic target for the treatment of myocardial infarction-induced heart failure. ACTA PHARMACOLOGICA SINICA. https://doi.org/10.1038/s41401-026-01827-4

Related articles

• Adenosine receptor signaling in vascular diseases: from molecular mechanisms to targeted therapeutics · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Macrophage FOLR2 drives liver fibrosis via intercellular engagement of TGFβRII · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Cardiomyocyte OTUD7b drives diabetic cardiomyopathy via deubiquitinating and stabilizing TAK1 · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Astrocytic adrenergic α2 receptor contributes to the mechanisms underlying the circadian rhythmicity of seizure susceptibility · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Serum/glucocorticoid-regulated kinase 1 regulates vascular inflammation in atherosclerosis · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• METTL3 loss exacerbates colitis via m6A-dependent Slc39a8 regulation and epithelial lineage depletion · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Secreted chimeric proteins as a strategy to correct SOX17 deficiency and attenuate the malignant phenotype of cholangiocarcinoma cells: a proof-of-concept study · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Activation of peripheral muscarinic receptors rescues depressive-like behaviors via gut-brain-axis, involving parasympathetic excitation · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal
• Structural basis for dual targeting of μ-opioid and nociceptin/orphanin FQ receptors by Cebranopadol · ACTA PHARMACOLOGICA SINICA · 2026 · Same journal